Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MK-2870-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2870-U01 Master Protocol to Evaluate the Safety and Efficacy of Sacituzumab Tirumotecan (Sac-TMT; MK-2870) Alone or in Combination for the Treatment of Participants With Metastatic Castration-Resistant Prostate Cancer/Androgen Pathway Modulator Refractory (mCRPC/APMR)

NCT07908524 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07908524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
MK-2870-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2870-U01 Master Protocol to Evaluate the Safety and Efficacy of Sacituzumab Tirumotecan (Sac-TMT; MK-2870) Alone or in Combination for the Treatment of Participants With Metastatic Castration-Resistant Prostate Cancer/Androgen Pathway Modulator Refractory (mCRPC/APMR)
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
December 14, 2026
Completion date
June 29, 2032
Enrollment
290 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer

Arms

As registered; 5 arms.

  • Docetaxel Active comparatorDocetaxel, Prednisolone, Prednisone

    Participants will receive docetaxel every 3 weeks by intravenous (IV) infusion. Participants will also receive either prednisone or prednisolone daily (or per approved product label).

  • Sac-TMT (Dose 1) ExperimentalRescue medication, Sacituzumab tirumotecan

    Participants will receive sac-TMT monotherapy every 2 weeks (q2w) by IV infusion.

  • Sac-TMT (Dose 2) ExperimentalRescue medication, Sacituzumab tirumotecan

    Participants will receive sac-TMT monotherapy q2w by IV infusion.

  • Sac-TMT Plus Opevesostat ExperimentalDexamethasone, Fludrocortisone, Opevesostat, Rescue medication, Sacituzumab tirumotecan

    Participants will receive sac-TMT q2w by IV infusion in combination with oral administration of opevesostat twice daily until any of the criterion for discontinuation are met. Participants receiving opevesostat will receive fludrocortisone and dexamethasone daily.

  • Sac-TMT Plus Androgen Receptor Pathway Inhibitor (ARPI): Abiraterone Acetate or Enzalutamide ExperimentalAbiraterone acetate, Enzalutamide, Prednisolone, Prednisone, Rescue medication, Sacituzumab tirumotecan

    Participants will receive sac-TMT q2w by IV infusion in combination with oral administration of an androgen receptor pathway inhibitor (ARPI), either abiraterone acetate daily or enzalutamide daily until any of the criterion for discontinuation are met. Participants receiving abiraterone acetate will also receive either prednisone or prednisolone daily (or per approved product label).

Primary endpoints

Registered primary outcome measures; 6 primary.

  • Efficacy Phase: Objective Response Rate (ORR) Up to approximately 66 months

    ORR is defined as the percentage of participants with complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Prostate Cancer Working Group 4 (PCWG4)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

  • Efficacy Phase: Number of Participants Who Experience at Least One Adverse Event (AE) Up to approximately 66 months

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience at least one AE will be reported.

  • Efficacy Phase: Number of Participants Who Discontinue Study Intervention Due to an AE Up to approximately 66 months

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

  • Safety Lead-In (Combination Arms Only): Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) Up to approximately 28 days

    DLT will be defined as any drug-related AE observed during the DLT evaluation period (up to 28 days after the first dose of study intervention or prior to the third dose, whichever occurs first) that results in a change to a given dose or a delay in initiating the next treatment. The number of participants who experience a DLT will be reported.

  • Safety Lead-In (Combination Arms Only): Number of Participants Who Experience at Least One AE Up to approximately 66 months

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience at least one AE will be reported.

+1 more primary endpoint

Lead sponsor's other trials

Merck Sharp & Dohme LLC, most recent start first.